Stay updated on SBRT+Nivolumab/Ipilimumab in RCC Clinical Trial
Sign up to get notified when there's something new on the SBRT+Nivolumab/Ipilimumab in RCC Clinical Trial page.

Latest updates to the SBRT+Nivolumab/Ipilimumab in RCC Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedAdded a Locations section with Maryland and Texas sites and UT Southwestern Medical Center as sponsor, and updated the revision to v3.3.3. The update also removes the HHS Vulnerability Disclosure link and the prior Maryland, Texas, and UT Southwestern Medical Center entries (v3.3.2).SummaryDifference0.4%

- Check28 days agoNo Change Detected
- Check49 days agoChange DetectedA new revision note, v3.3.2, was added and the older v3.2.0 revision was removed. There are no changes to the study content or user-facing information.SummaryDifference0.1%

- Check57 days agoChange DetectedNotice about government funding status (an ancillary alert) was removed from the page, which does not affect the study details or how to use the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check71 days agoChange DetectedThe new screenshots show cosmetic formatting updates without changes to study content, eligibility criteria, endpoints, or contacts. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check100 days agoChange DetectedUpdated operating-status notice and version 3.2.0; removed version 3.1.0.SummaryDifference3%

- Check107 days agoChange DetectedVersion update: from v3.0.2 to v3.1.0. The change is limited to the revision label; no core content or critical data appears to be altered.SummaryDifference0.1%

Stay in the know with updates to SBRT+Nivolumab/Ipilimumab in RCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SBRT+Nivolumab/Ipilimumab in RCC Clinical Trial page.